Terns Pharmaceuticals, Inc.
TERN
$2.92
-$0.13-4.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -18.69% | -21.28% | 53.47% | 62.94% | 74.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.67% | 4.88% | 36.24% | 43.51% | 65.34% |
| Operating Income | 0.67% | -4.88% | -36.24% | -43.51% | -65.34% |
| Income Before Tax | 1.53% | -3.90% | -33.56% | -34.08% | -49.98% |
| Income Tax Expenses | 8.79% | -47.05% | -42.76% | -30.48% | -33.24% |
| Earnings from Continuing Operations | 1.50% | -3.60% | -33.07% | -33.71% | -49.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.50% | -3.60% | -33.07% | -33.71% | -49.49% |
| EBIT | 0.67% | -4.88% | -36.24% | -43.51% | -65.34% |
| EBITDA | 0.70% | -4.88% | -36.45% | -43.93% | -66.16% |
| EPS Basic | 10.99% | 6.81% | -2.12% | 20.62% | 30.50% |
| Normalized Basic EPS | 11.02% | 6.47% | -2.48% | 20.50% | 30.41% |
| EPS Diluted | 10.99% | 6.81% | -2.12% | 20.62% | 30.50% |
| Normalized Diluted EPS | 11.02% | 6.47% | -2.48% | 20.50% | 30.41% |
| Average Basic Shares Outstanding | 11.55% | 11.83% | 24.91% | 53.82% | 98.22% |
| Average Diluted Shares Outstanding | 11.55% | 11.83% | 24.91% | 53.82% | 98.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |